Tandem mass spectrometry of globotriaosylceramide: quantification in plasma and urine for diagnosis and therapy monitoring in Fabry disease

Abstrakt

Objective: An assay for measuring globotriaosylceramide (Gb3Cer) levels in plasma and urine of patients with Fabry disease (FD) has been established.